ETFS Holding Amgen Inc

 
ETF Quotes for ETFS Holding Amgen Inc top ^
  • Holdings: Johnson & Johnson , Pfizer Inc , Merck & Co Inc , Gilead Sciences Inc , Amgen Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for iyh investment picks
  • Holdings: Biogen Idec Inc , Celgene Corp , Gilead Sciences Inc , Amgen Inc , Regeneron Pharmaceuticals Inc ,
  • Morningstar Rating: 5 Stars
Sign-up for ibb investment picks
  • Holdings: Johnson & Johnson , Pfizer Inc , Merck & Co Inc , Gilead Sciences Inc , Amgen Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for xlv investment picks
  • Holdings: Gilead Sciences Inc , Amgen Inc , Celgene Corp , Biogen Idec Inc , Biomarin Pharmaceutical Inc ,
  • Morningstar Rating: 5 Stars
Sign-up for bbh investment picks
  • Holdings: Johnson & Johnson , Pfizer Inc , Merck & Co Inc , Gilead Sciences Inc , Amgen Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for vht investment picks

 
Stock Quotes for Amgen Inc top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Core
  • Stock Type: Slow Growth
  • Morningstar Rating: 4 Stars
Sign-up for amgn investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Core
  • Stock Type: Slow Growth
  • Morningstar Rating: 4 Stars
Sign-up for amgn investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Core
  • Stock Type: Speculative Growth
Sign-up for amg%20n investment picks

 
News Articles for Amgen Inc top ^
2014/12/3
THOUSAND OAKS, Calif.
Sign-up for Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition investment picks
2014/12/3
Quimioterapia: Mitos y Realidades Aimed at Helping Spanish-Speaking Patients and Caregivers Take Control of Their Chemotherapy Journey THOUSAND OAKS, Calif.
Sign-up for Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources investment picks
2014/12/6
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
2014/12/6
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
2014/12/8
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif.
Sign-up for Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia investment picks
2014/12/8
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif.
Sign-up for New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma investment picks
2014/12/8
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif.
Sign-up for FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy investment picks
2014/12/11
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
2015/1/5
By Tess Stynes Amgen Inc. and Kite Pharma Inc. reached a research collaboration and license agreement to develop cancer immunotherapy treatments that focus on Amgen's array of cancer targets and Kite Pharma's autologous cell therapy platform.
Sign-up for Amgen and Kite Pharma in cancer immunotherapy pact investment picks
2015/1/5
Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates Kite to Receive a $60 Million Upfront Payment From Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite's Intellectual Property for CAR T Cell Products Amgen Eligible to Receive up to $525 Million in Milestone Payments per Kite Program; Plus, Tiered Single-Digit Sales Royalties Kite to Host Conference Call Today at 4:00 PM Eastern Time THOUSAND OAKS, Calif.
Sign-up for Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies investment picks
2014/12/22
Sponsorship Secures Resources Needed for Biotech Startups to Advance Innovative Research CAMBRIDGE, Mass.
Sign-up for Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts investment picks
2014/12/17
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Amgen Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Ametek, Inc.  |  Next: ETFS Holding Amkor Technology Inc